Mifamurtide

Base Information

• Chemical Name: Mifamurtide
• CAS No.: 83461-56-7
• Molecular Formula: C59H109N6O19P
• Molecular Weight: 1237.5
• UNII: 1LM890Q4FY
• NCI Thesaurus Code: C1394
• Metabolomics Workbench ID: 154407
• Mol file: 83461-56-7.mol

Synonyms:CGP 19835 A;CGP-19835A;Mepact;mifamurtide;mifamurtide acid;mifamurtide anhydrous;mifamurtide free acid anhydrous;mifamurtide sodium;mifamurtide sodium salt;MLV 19835;muramyl tripeptide phosphatidylethanolamine;muramyl tripeptide phosphatidylethanolamine, monosodium salt;muramyl tripeptide phosphatidylethanolamine, sodium salt;muramyl tripeptide-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine conjugate;muramyl tripeptide-1,2-dipalmitoylphosphatidylethanolamine conjugate;muramylNAc-Ala-isoGln-Lys-tripeptide-PE;muramylNAc-Ala-isoGln-Lys-tripeptide-phosphatidylethanolamine;N-acetylmuramyl-alanyl-isoglutaminyl-alanyl-sn-glycero-3-phosphoethanolamine

Chemical Property of Mifamurtide

Chemical Property:

• Refractive Index: 1.505
• PKA: 1.39±0.50(Predicted)
• PSA: 385.91000
• Density: 1.152 g/cm³
• LogP: 8.41710
• Storage Temp.: ?20°C
• Solubility.: water: soluble2mg/mL, clear (warmed)
• Hydrogen Bond Donor Count: 10
• Hydrogen Bond Acceptor Count: 20
• Rotatable Bond Count: 58
• Exact Mass: 1276.74102120
• Heavy Atom Count: 87
• Complexity: 1950

Purity/Quality:

98%,99%, ^*data from raw suppliers

Mifamurtide ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(C(=O)N)NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(=O)C)C(C(CO)O)O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+]
• Isomeric SMILES: CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(=O)N)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]([C@H](C=O)NC(=O)C)[C@@H]([C@@H](CO)O)O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+]
• Uses: Osteosarcoma. Mifamurtide may be used in immunological and cancer-related cell signaling studies.
• Clinical Use: Mifamurtide is an anticancer agent for the treatment of osteosarcoma, the most common primary malignancy of bone tissue mainly affecting children and adolescents. The drug was invented by Ciba-Geigy (now Novartis) in the early 1980s and the agent was subsequently licensed to Jenner Biotherapies in the 1990s. IDM Pharma bought the rights to the drug from Jenner in April 2003.In March 2009, mifamurtide was approved in the 27 European Union member states plus Iceland, Liechtenstein and Norway via a centralized marketing authorization. After the approval, IDM Pharma was acquired by Takeda, which began launching mifamurtide, as Mepact ?, in February 2010. Mifamurtide, a fully synthetic lipophilic derivative of muramyl dipeptide (MDP), is muramyl tripeptide phosphatidylethanolamine (MTP-PE), which is formulated as a liposomal infusion.
• Drug interactions: Potentially hazardous interactions with other drugs Analgesics: avoid with high dose NSAIDs. Ciclosporin: avoid concomitant use. Corticosteroids: avoid concomitant use. Tacrolimus: avoid concomitant use.